Boris Mankovsky
Boris Mankovsky
Shupyk National Medical Academy of Postgraduate Education
Підтверджена електронна адреса в
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
MDR Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W ...
N Engl J Med. 377 (7), 644-657, 2017
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
WB White, CP Cannon, SR Heller, SE Nissen, RM Bergenstal, GL Bakris, ...
N Engl j Med 369, 1327-1335, 2013
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
P Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM ...
N Engl J Med 380 (24), 2295-2306, 2019
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
H Haller, S Ito, JL Izzo Jr, A Januszewicz, S Katayama, J Menne, ...
New England Journal of Medicine 364 (10), 907-917, 2011
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
AF Hernandez, JB Green, S Janmohamed, RB D'Agostino Sr, CB Granger, ...
The Lancet 392 (10157), 1519-1529, 2018
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial
N Sherry, W Hagopian, J Ludvigsson, SM Jain, J Wahlen, RJ Ferry Jr, ...
The Lancet 378 (9790), 487-497, 2011
Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients
D Ziegler, L Movsesyan, B Mankovsky, I Gurieva, Z Abylaiuly, I Strokov
Diabetes care 32 (8), 1479-1484, 2009
Cerebrovascular disorders in patients with diabetes mellitus
BN Mankovsky, BE Metzger, ME Molitch, J Biller
Journal of diabetes and its complications 10 (4), 228-242, 1996
Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind …
RE Ratner, J Rosenstock, G Boka, DRI6012 Study Investigators
Diabetic Medicine 27 (9), 1024-1032, 2010
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
M Nowicki, I Rychlik, H Haller, ML Warren, L Suchower, I Gause‐Nilsson, ...
Diabetes, Obesity and Metabolism 13 (6), 523-532, 2011
The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Am J Nephrol 46 (6), 462-472, 2017
Stroke in patients with diabetes mellitus
BN Mankovsky, D Ziegler
Diabetes/metabolism research and reviews 20 (4), 268-287, 2004
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial
W Hagopian, RJ Ferry, N Sherry, D Carlin, E Bonvini, S Johnson, KE Stein, ...
Diabetes 62 (11), 3901-3908, 2013
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
ZD Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF ...
Lancet 393 (10184), 1937-1947, 2019
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial
RS Rosenson, C Hislop, D McConnell, M Elliott, Y Stasiv, N Wang, ...
The Lancet 373 (9664), 649-658, 2009
Ticagrelor in Patients with Stable Coronary Disease and Diabetes
LLA Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C ...
N Engl J Med. 381 (14), 1309-1320, 2019
Impairment of cerebral autoregulation in diabetic patients with cardiovascular autonomic neuropathy and orthostatic hypotension
BN Mankovsky, R Piolot, OL Mankovsky, D Ziegler
Diabetic medicine 20 (2), 119-126, 2003
Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
C G Fulcher 1 , D R Matthews , V Perkovic , D de Zeeuw , K W Mahaffey , C ...
Diabetes Obes Metab . 18 (1), 82-91, 2016
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo …
DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ...
The Lancet 394 (10204), 1169-1180, 2019
Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis
L Lauf, Z Ozsvár, I Mitha, J Regöly-Mérei, JM Embil, A Cooper, MB Sabol, ...
Diagnostic microbiology and infectious disease 78 (4), 469-480, 2014
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20